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Abstract
Novel murine models of retinoblastoma based on Rb gene deletion in concert with inactivation of
Rb  family members have recently been developed. These new Rb  knockout models of
retinoblastoma provide excellent tools for pre-clinical studies and for the exploration of the
genetics of tumorigenesis driven by RB inactivation. This review focuses on the developmental
consequences of Rb deletion in the retina and the genetic interactions between Rb and the two
other members of the pocket protein family, p107 (Rbl1) and p130 (Rbl2). There is increasing
appreciation that homozygous RB mutations are insufficient for human retinoblastoma. Identifying
and understanding secondary gene alterations that cooperate with RB inactivation in tumorigenesis
may be facilitated by mouse models. Recent investigation of the p53 pathway in retinoblastoma, and
evidence of spatial topology to early murine retinoblastoma are also discussed in this review.
Introduction
Retinoblastoma is the most common pediatric primary
intraocular tumor. Study of retinoblastoma, a malignant
cancer that occurs unilateral or a bilateral form, led to the
"two-hit hypothesis" now applicable to other inherited
cancer syndromes [1]. In bilateral retinoblastoma, an
inherited or de novo germline mutation in one RB allele is
typically observed, with such mutations identified in
approximately 90% of patients, and the second RB allele
undergoes somatic mutation [2,3]. In sporadic, unilateral
retinoblastoma, somatic mutations occur in both RB alle-
les. The RB  gene was the first tumor suppressor gene
cloned [4], and RB is now known to be mutated not only
in retinoblastoma but in many cancers, including osteosa-
rcoma, soft tissue sarcoma, small cell lung, breast, brain,
prostate, leukemia, and other sporadic cancers [5-9].
Patients with germline RB mutation are at increased risk
for many of these tumor types and for melanoma [10-12].
They are also at risk for "trilateral retinoblastoma", involv-
ing a pediatric midbrain tumor (pinealoblastoma or
suprasellar primitive neuroectodermal tumor) in addition
to retinoblastoma [13,14]. Even though RB is mutated
widely in various human tumor types, the retina is exqui-
sitely sensitive to cancer upon RB loss and the reason for
this is tissue sensitivity is still poorly understood. Our cur-
rent knowledge of RB function places this gene in path-
ways central to growth control not only in the retina, but
in all tissues. RB is a prototypic tumor suppressor gene
that encodes pRB, a nuclear phosphoprotein implicated
in cell cycle control, differentiation, apoptosis, and many
other biological processes. Despite intensive study of this
tumor suppressor gene since its cloning, the critical func-
tions of pRB important for tumor suppression are still
being unraveled.
Biological functions of the pRB family
pRB is one member of the "pocket proteins", a family that
also includes p107 and p130. These proteins are named
owing to the presence of a conserved pocket domain, a
region that binds E2F transcription factors and various
critical protein interactors, many containing an LxCxE
motif. The three pocket proteins exhibit similarities, par-
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ticularly in the A and B pocket, but there are also clear dif-
ferences. p107 and p130 have much closer similarity to
each other than either to pRB. The pocket proteins differ
in their expression patterns, with p107 highly expressed in
cycling cells, and p130 expressed at higher levels in cells
that have exited the cell cycle [15]. Critical to the function
of the pocket proteins are the E2F transcription factors
[16]. Pocket proteins can inhibit E2F transactivation activ-
ity directly by interfering with the E2F transactivation
domain. Also, pocket proteins form complexes with his-
tone deacetylases, histone methyltransferases, histone
demethylases, and other chromatin modulators, which
act to confer a repressive chromatin state around E2F tar-
get genes. There are now 8 known E2Fs, including E2F1
through 8. E2Fs 1–5 act in concert with a DP protein part-
ner to bind the pRB family; pRB binds the so-called acti-
vating E2Fs, E2F1, 2, 3a, which have a nuclear localization
signal and are strong transcriptional activators. pRB also
binds E2F4. p107 and p130 bind E2F4 and 5, often
referred to as repressive E2Fs, although p107 and p130
can also form complexes with activating E2Fs under some
conditions [17]. E2Fs 6–8 do not function through pocket
protein binding. Pocket protein/E2F complexes are
dynamic and change upon progression through the cell
cycle [18]. The extent to which specific E2Fs mediate
pocket protein function and whether E2Fs are the most
critical effectors are important questions. The three pocket
proteins differ in many binding partners in addition to
E2Fs. For example, p130 but not pRB, interacts with mem-
bers of the DREAM complex, which binds to many pro-
moters and acts to repress cell cycle genes in quiescent
cells [19-21]. Notably, this complex includes homologs of
C elegans SynMuvB genes (important for vulval develop-
ment) and Drosophila melanogaster dREAM (drosophila
RBF, E2F and Myb-interacting) complex members. There
is also evidence that pRB may bind pro- differentiation
factors, such as CBFA1, MITF, C/EPBs and MyoD to pro-
mote cell type specific differentiation [22-25]. Data impli-
cating pRB in differentiation control suggest that pRB
functions as a positively activating transcriptional co-acti-
vator, which is very different from the well-characterized
repressive effects of pRB on E2F activity in cell cycle con-
trol. The specific effectors for RB  family members that
contribute to retinoblastoma are not well understood.
Here, we focus on insights that study of the murine Rb
family function in the retina in vivo have for understand-
ing human retinoblastoma.
Retinal Development
The neural retina is composed of seven classes of cell types
derived from a common population of progenitors, with
cell bodies organized into three nuclear layers. The outer
nuclear layer contains cell bodies for rod and cone pho-
toreceptors; the inner nuclear layer contains bipolar, ama-
crine, horizontal and Müller glia cell bodies, and the
ganglion cell layer is made up of ganglion and amacrine
cells (Fig 1A). Development of the retina occurs in embry-
onic and postnatal stages in mice; in humans, retinogene-
sis is thought to cease near birth [26,27]. The retina
derives from anterior tube neuroepithelium that under-
goes a lateral bulge after neural tube closure, forming the
optic vesicle (reviewed in [28]). Invagination of the cen-
tral part of the optic vesicle leads to formation of a bilay-
ered optic cup, with an inner layer that forms neural
retina, and an outer layer that forms the retinal pigment
epithelium. Progenitor cells undergo mitosis along the
outer edge of the retina in the retinal ventricular zone.
Interkinetic migration occurs such that nuclei migrate
away from this zone to undergo G1, S and G2 cycle stages
and return for the next mitosis [27]. Lineage tracing stud-
ies using retroviral vectors have revealed that mature reti-
nal cell types derive from multipotent progenitors.
Potency differs as development proceeds, such that
embryonic mitotic clones can contain almost all possible
cell types, while postnatal clones are more restricted
[29,30]. However, even at late postnatal stages in rodents,
2-cell clones can contain both a Müller glia cell and a rod
photoreceptor illustrating multipotency even up until the
last cell division [30]. Following cell cycle exit, cells differ-
entiate, migrate to the correct layer and establish appro-
priate synaptic connections. The developing retina is a
simple and very well characterized region of the central
nervous system with a defined order of cell type genera-
tion, markers for each cell type, and spatial localization of
cells at different stages of the cell cycle. Also, the retina is
accessible to manipulation in vivo using plasmid electro-
poration, or, if stable expression over many cell divisions
is needed, viral vectors. These properties make the retina
an ideal system to study not only development, but also
cancer initiation. For childhood cancers these processes
are clearly intertwined.
Human retinoblastoma
Retinoblastoma is a pediatric cancer that is typically
detected in the first few years of life but can arise during
embryonic retinal development [31]. The identity of the
specific cell from which retinoblastoma arises is
unknown. It has been proposed that retinoblastoma arises
from a primitive neuroectodermal cell with multipotent
potential [32]. Histologically, retinoblastomas exhibit
neuronal differentiation and exhibit focal regions that
contain rosettes. Homer-Wright rosettes, indicative of
neuroblastic differentiation are present in retinoblastoma
and various neuroectodermal tumors (Fig 1b). Flexner-
Wintersteiner rosettes exhibit ultrastructural evidence of
photoreceptor differentiation [33,34]. Primitive outer seg-
ments in such rosettes stain positively for markers of pho-
toreceptor antigens such as interphotoreceptor binding
protein (IRBP) and opsins (See Fig. 1c). The rod photore-
ceptor rhodopsin was found in Flexner-WintersteinerCell Division 2008, 3:9 http://www.celldiv.com/content/3/1/9
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rosettes in most tumors examined [35,36] and, in a sepa-
rate study, both rod and cone markers were expressed in
many retinoblastomas, with increased staining of cone
markers over rod markers [37]. The stronger cone charac-
ter of retinoblastoma is also supported by studies of a
number of cell lines, which revealed mRNA for cone but
not rod cGMP phosophdiesterase, and cone transducins
[38,39]. Together, these observations have led to a view
that retinoblastoma is derived from a developing photore-
ceptor or a cell with the potential to adopt a photorecep-
tor cell fate. The question of whether the retinoblastoma-
originating cell is a post-mitotic cell specified to become a
photoreceptor (i.e. a transition cell), or a restricted pro-
genitor, or a broadly multipotent cell capable of forming
many cell types must be resolved.
Lineage tracing studies in the normal rodent retina do not
support the existence of specific progenitors that generate
only rod and cone photoreceptors [30]. Instead, such
studies have revealed that normal retinal progenitor cells
are multipotent; clones containing cones, an early born
cell type, almost always included different cell types as
well [29]. If retinoblastoma is derived from a progenitor
cell capable of forming cone photoreceptors, than such a
cell would be expected to have broad potency. While
much of the focus of retinoblastoma cell of origin studies
has been on photoreceptors, inner cell layer markers have
also been detected in retinoblastoma [40]. Also, early
retinoblastomas sometimes appear to emerge from the
inner nuclear layer and not the photoreceptor layer impli-
cating a possible inner layer cell-of-origin [41]. There are
many reports describing Müller cells in retinoblastoma
[42,43], but it has been debated whether such cells are
neoplastic, as opposed to reactive non-tumor cells [44].
Findings that retinoblastoma cells in culture can be
induced to express glial markers and exhibit the potential
to differentiate into neuron or glial cells support the idea
that retinoblastomas arise from multipotent progenitor
cells [32]; however, direct evidence of neoplasia in Müller
cells from retinoblastoma cells that have not undergone
long term culture is needed. Observations that normal
progenitor cells in rodents can generate clones containing
rods, cones, Müller glia and other cells [29] support the
idea that cell type heterogeneity in retinoblastoma may be
due to transformation of a progenitor that is normally
multipotent, but dedifferentiation or trans-differentiation
of a cell-type specified cell-of-origin cannot be ruled out.
More recently, stem cell markers have been found
expressed in human retinoblastoma cell lines, such as
Oct3/4 and Nestin [45,46]. Overall, the human data sug-
gest tumor origin in a multipotent cell but the extent to
which these cells are multipotent requires further exami-
nation.
There are limitations to using human tumor samples to
identify the tumor cell of origin. In the establishment and
long term passaging of cell lines, genetic alterations may
occur that alter the cell's properties. Also, accessing early
retinoblastomas is rarely possible, limiting analysis to late
stage tumors that may have quite different characteristics
compared to the earliest lesions. Use of model systems
can help in assessing the early events in tumorigenesis.
Transgenic retinoblastoma models
A number of models of retinoblastoma have been devel-
oped that have made use of transgenic expression of spe-
cific viral oncoproteins. The most widely used such
model, the LH-beta T-Ag model expresses the SV40 early
region under control of the Luteinizing hormone beta
promotor [47]. The development of retinoblastomas in
one LH-beta T-Ag line was in part a consequence of the
genomic site of integration directing transgene expression
to cells in the retina, a tissue in which luteinizing hor-
mone beta is not normally expressed. Both Large-T and
small-t oncoproteins are encoded by the SV40 early region
and may contribute to tumorigenesis. Large-T Ag binds
the pRB family, p53, and other proteins, such as CBP/
p300. Small-t Ag also contributes to transformation in cell
culture, in part through binding the phosphatase pp2A
[48]. In the LH-beta T-Ag model, retinoblastoma with neu-
ronal characteristics and histological similarities to
human retinoblastomas emerged. Transgenic mice
expressing T-Ag/t-Ag from the IRBP promoter have also
been generated and develop retinoblastoma [49-51]. IRBP
is expressed not only in photoreceptor cells but in some
progenitor cells [52], raising the possibility of a progeni-
tor or newly post-mitotic cell of origin. Also, Phenyleth-
anolamine N-methyltransferase-driven T-Ag (PNMT-T-
Ag) transgenic mice develop retinal tumors that arise at
the retina periphery. This spatial localization of retinal
tumors in mice occurred despite T-Ag/t-Ag being
expressed in amacrine and horizontal cells in both central
and peripheral retina [53,54]. The authors suggest that the
tumors arise from amacrine or horizontal cells [54] but it
is not clear why the tumors were peripheral as these cell
types are present throughout the retina.
Papillomavirus E7 protein binds to the pocket protein
family, and other effectors, but does not inactivate p53.
IRBP-E7  mice underwent photoreceptor degeneration,
while IRBP-E7; p53-/- animals were prone to tumors of the
retina that arise in the photoreceptor layer [55]. While ini-
tially, it was proposed that p53  loss suppressed E7-
dependent apoptosis, leading to retinoblastoma, p53 loss
may contribute in other ways, as these tumors are now
recognized to emerge in the midst of high levels of apop-
tosis and photoreceptor degeneration even upon p53 defi-
ciency [56]. This distinction is important, as in other
mouse models, there is good evidence that functions ofCell Division 2008, 3:9 http://www.celldiv.com/content/3/1/9
Page 4 of 16
(page number not for citation purposes)
p53 independent of apoptosis are critical for tumor sup-
pressor ability [57]. This is also relevant to a renewed
interest in the role of p53 in retinoblastoma discussed fur-
ther on in this review. Whether the tumors in the IRBP-
E7;p53-/-, LH-beta T-Ag and PNMT-Tag models exhibit a
similar cell of origin or if these models represent distinct
tumors of different cell types remains to be determined.
Use of transgenic retinoblastoma models has been valua-
ble for the testing of preclinical therapeutics; however, the
development of models that target Rb but not other effec-
tors of viral oncoproteins has been a clear goal for
improvement of mouse retinoblastoma models. The main
disadvantage of transgenic models expressing viral onco-
proteins concerns the pleiotropic effects of the oncopro-
teins, which impact upon multiple signaling pathways.
These oncoproteins may also have important targets not
yet identified. Furthermore, tumors in which p53 is func-
tionally ablated through T-Ag expression are not ideal for
testing therapies, whose effectiveness may depend on the
p53 pathway being intact [58,59].
"Rb knockout" models of retinoblastoma
The generation of mouse models that, like human retino-
blastoma, exhibit Rb  deletion took a number of years.
Three groups inactivated Rb in the mouse germline, result-
ing in embryonic lethality in Rb-/- animals and the devel-
opment of pituitary and thyroid tumors in Rb+/- animals
[60-62]. Retinoblastomas never occurred in the murine Rb
heterozygotes, in stark contrast to the high retinoblastoma
incidence in humans with germline RB  mutation. The
Jacks and the Berns groups both generated chimeric ani-
mals in which Rb-/- cells contributed to the retina, but
retinoblastomas still did not form [63,64]. With the gen-
eration of chimeric animals lacking Rb and p107 came the
realization that mice were capable of developing retino-
blastoma dependent on Rb deletion [65]. However, the
study of large numbers of retinoblastoma-bearing ani-
mals was not practical using this chimera model. Indeed,
the low recovery of viable chimeras suggested significant
developmental lethality upon high contribution of Rb-/-;
p107-/- cells to the developing embryo.
Nevertheless, the advent of Cre-lox technology and Cre-
expressing transgenic animals with expression in the
developing retina paved the way for the generation of
breedable  Rb-knockout models of retinoblastoma. The
first attempt, based upon the previous descriptions of
photoreceptor characteristics in retinoblastoma used Cre
regulated by the IRBP promoter together with RbLox alleles
to drive Rb deletion in the photoreceptor compartment
and in other tissues [66]. These mice did not develop
retinoblastoma, even when combined with both p107 and
p53 deficiency, indicating that the tumor-initiating cells in
Rb/p107 DKO chimeras were not being targeted when
these genes were deleted in developing photoreceptors.
Breedable  Rb-knockout models of retinoblastoma were
independently generated using Cre  transgenics with
expression driven by Nestin, Chx10 and Pax-6 promoter in
progenitor and other cells [67-70]. New retinoblastoma
models confirmed the tumor suppressor function of p107
first revealed in chimera studies. Mouse models have now
revealed that inactivation of the third pocket protein,
p130, also cooperates very strongly with Rb deletion to
promote retinoblastomas in both Rb knockout and chi-
meric mice [68,69,71]. A summary of the different Rb-
knockout and chimeric retinoblastoma models is pro-
vided in Table 1. The breedable Rb knockout models of
retinoblastoma now provide excellent tools to hone in on
Table 1: Rb-/- mouse models of retinoblastoma
Model Frequency Tumor Characteristics References
Rb-/-p107-/- chimeras 5/7 mice (1/5 bilateral) Positive staining for amacrine markers, some Müller cells present [65]
Rb-/-p130-/- chimeras 5/11 mice (2/5 bilateral) Positive staining for amacrine markers, some Müller cells present
Average 3 months to tumor detection
[71]
α-Cre; Rblox/lox; p107-/- > 60% Positive staining for amacrine markers, some Müller cells present
Average 280 days to externally visible retinoblastoma
[67, 68]
α-Cre; Rblox/lox; p130-/- 29/29 mice (bilateral) Positive staining for amacrine and horizontal markers, some
Müller cells present
Average 128 days to externally visible retinoblastoma
Lymph node and brain metastasis
[68]
NesCre1; Rblox/lox; p130-/- 5/5 mice (4/5 bilateral) Positive staining for amacrine markers, some Müller cells present [69]
Chx10Cre; Rblox/lox; p107-/- ~60% Positive staining for amacrine, horizontal and progenitor markers [89]
Chx10Cre; Rblox/lox; p107-/-; p53-/- 100% (bilateral) Positive staining for amacrine, horizontal and progenitor markers
Increase in less differentiated cells vs. Chx10Cre; Rblox/lox
p107-/- tumors
Average 100 days before mice were moribund
[70, 89, 129]
Chx10Cre; Rblox/lox; p130-/-;p107+/- 45/45 mice (bilateral) Positive staining for horizontal cell markers in primary tumors
Metastastes did not stain for horizontal cell markers
Tumors arose at 8-14 weeks
[95]Cell Division 2008, 3:9 http://www.celldiv.com/content/3/1/9
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the cell of origin and interrogate the molecular genetics of
retinoblastoma progression.
Rb in murine retinal development
Retinoblastoma is a clear example of a tumor with devel-
opmental origins and, as such, it's understanding requires
knowledge of the normal developmental role of Rb in the
retina. Homozygous germline Rb deletion in mice leads to
embryonic lethality in midgestation, caused by placental
deficiency [60-62,72]. Rb has been inactivated in the ret-
ina using a number of different systems that bypass the
lethality associated with systemic Rb deletion. Rb-/-;+/+
chimeric animals and various Cre-expressing transgenics,
including  Chx10-cre,  Pax6  α-enhancer Cre (α-Cre) and
NesCre1, in concert with an Rb lox/lox allele exhibit Rb
deletion in the retina [67,69,73]. These models inactivate
Rb at different times and in different cells. Chx10-Cre is
expressed in a mosaic pattern in progenitor cells, and in
adults is expressed in most bipolar cells and in some
Müller cells [73]. NesCre1 is active in the optic vesicle by
E9.5 and exhibits different expression upon paternal vs.
maternal inheritance of the transgene [69]. Complete
recombination in the retina occurs upon paternal Cre
transmission and is accompanied by lethality at birth in
Rblox/lox animals. A mosaic pattern of Cre  expression is
observed with maternal NesCre1 inheritance allowing for
the survival of some animals on an Rblox/lox background. α-
Cre is expressed by E10.5 in distal progenitor cells, with a
dorsal gap in expression [74]. In addition to the wide-
spread expression in peripheral progenitors, certain cells
in the inner nuclear layer and ganglion cell layer express
α-Cre at late stages both in central and peripheral retina.
A synthesis of the data from many groups using different
systems has revealed common phenotypes that have
implicated Rb in control of proliferation, apoptosis and
differentiation in the developing retina (Table 2).
In embryonic stages of retinal development, the first indi-
cation that there were cell cycle defects upon Rb deletion
came from Rb-/-;Rb+/+chimeric animals in which mitotic
figures and high levels of cell death were found in the
inner retina from E16.5 to E18.5 [63]. Ectopic prolifera-
tion in the retinal ganglion cell layer has been observed as
early as E13.5 in germline Rb mutants [75]. Ectopic prolif-
eration coupled to apoptosis in the inner embryonic Rb-/-
retina was also observed in α-Cre  and  Nes-Cre1  mice
[67,69]. Normal retinal mitoses are restricted to the outer
edge of the retina and never occur in the differentiating
inner region suggesting that differentiating Rb-/-  cells
exhibit defects in exiting the cell cycle. The most pro-
nounced effects of Rb deletion are seen in late stages of ret-
inal development, as Rb  loss causes the proliferative
period of retinogenesis to be extended [67-69]. Notably,
the inappropriately proliferating Rb-/- cells at early and
late developmental stages express markers associated with
differentiation of each of the seven classes of retinal cell
types, leading to the idea that Rb deletion primarily causes
normally post-mitotic, cell-type specified cells (termed
transition cells, or precursor cells) to proliferate inappro-
priately [67]. However, differentiation markers may also
be expressed in cells that have not yet committed to a cer-
tain cell fate, and it is possible that both progenitor cells
and transition cells are affected by Rb loss [76]. Impor-
tantly, cells in the Rb-deficient retina ultimately exited the
cell cycle or died such that by PND21, Rb-/- cells no longer
proliferate, and retinoblastoma never develops [67,68].
Interestingly, the high level of apoptosis that occurs upon
Rb deletion differentially affects specific cell types. Bipolar
cells, ganglion cells as well as the majority of rod photore-
ceptors are lost in α-Cre Rblox/lox mice. Photoreceptor apop-
tosis is specific to rods, as cells expressing cone markers
were present in normal numbers, revealing specificity to
rod cell death [67]. The cell death data are consistent with
results from Rb -/-; +/+ chimeras, in which there was a low,
but not null, contribution of Rb-/- cells to the adult retina
[63].
Finally, Rb loss has been associated with differentiation
defects. Rod photoreceptors in Chx10Cre Rblox/loxmice have
been reported to exhibit an altered pattern of heterochro-
matin suggestive of rod maturation defects [73,77,78]. It
has been argued that differentiation defects represent
direct effects of Rb loss, but it is difficult to distinguish
between downstream effects of Rb loss on cell cycle con-
trol vs. direct effects on differentiation. Interestingly,
defects in rod development were not found when IRBP-
Cre was used to drive Rb deletion in photoreceptor transi-
tion cells [66]. One explanation is that rod differentiation
requires pRB only at a progenitor stage prior to IRBP
expression but not at later stages. It will be important to
precisely determine the specific stage in rod development
that is affected. Expression of genes associated with rod
synaptogenesis were not altered in Rb-/- explant cultures
or in Chx10Cre Rblox/lox retinas [78], suggesting that the
rods are not completely blocked at a progenitor stage.
Nevertheless, some cells express progenitor cell markers in
the outer nuclear layer in Chx10Cre Rblox/lox animals [77];
these may be undifferentiated rods, but the possibility
that cells other than photoreceptor cells may have inap-
propriately migrated to the outer nuclear layer compli-
cates their identification. NesCre1, Chx10Cre and α-Cre
Rblox/lox mice all exhibit the presence of ectopic cells in the
outer plexiform layer that extend to the photoreceptor
layer [69,78], and the origin of these cells has not been
determined. Other differentiation defects in Rb-mutant
retinas have also been noted. Rb-deficient starburst ama-
crine cells were found to lack the expression of markers
associated with their maturation [79]. Also, a subset of Rb-
deficient horizontal cells exhibit enlarged abnormally
shaped nuclei, reminiscent of polyploid cells that haveCell Division 2008, 3:9 http://www.celldiv.com/content/3/1/9
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undergone endoreduplication in other Rb-deficient cell
types, such as skeletal muscle and Purkinje cells [64,69].
Defects in Rb-deficient horizontal cells involving ectopic
processes that extend into the outer nuclear layer have
also been described [77].
While there are many similarities between the phenotypes
observed following Rb  deletion using chimera systems
and different Cre-transgenic lines (Table 2), some differ-
ences have also been found. Overall, milder proliferative
and apoptotic phenotypes have been reported in studies
using Chx10Cre-mediated Rb  deletion versus other sys-
tems to inactivate Rb in the retina (Table 2). For example,
while bipolar cells undergo cell death in αCre Rblox/lox reti-
nas [67,69], this phenotype has not been observed in
Chx10Cre Rblox/lox retinas [78]. Differences in genetic back-
ground across different strains could contribute to differ-
ing phenotypes. It is also possible that differences in the
timing of Cre  expression across various cell types may
underlie the differing phenotypes observed. Endogenous
retinal Chx10, like Chx10Cre, is expressed not only in pro-
genitor cells, but, later in retinal development, in mature
inner nuclear cells including bipolar cells [73,80]. If het-
erogeneity in the timing of Rb deletion across different
cells occurs in animals exhibiting a mosaic pattern of Cre
expression, different phenotypes may result. Whether Rb
is required to maintain cell cycle exit, cell survival and/or
differentiation characteristics when deleted late in retinal
development is not known and will be important to deter-
mine. A second possibility is that in regions of extensive
Rb  deletion, non-cell-autonomous effects contribute to
the death of rod, bipolar and ganglion cells. To determine
if effects of Rb deletion are cell autonomous, the ideal
experiment involves stably marking the daughters of
mitotic cells using replication-deficient retroviral vectors
[81]. Lineage tracing experiments using a retrovirus to
express Cre recombinase in newborn animals followed by
analysis of clone composition have suggested that defects
in rod photoreceptors are cell autonomous [73]. In the
same study, while 12 of 115 control clones in Rblox/+ ani-
mals contained bipolar cells following Cre expression, 0
of 82 clones in Rblox/- animals contained bipolar cells (data
from Supplemental Table 2 in [73]). A similar lack of
bipolar-containing clones was observed upon functional
pRB inactivation through expression of E1A. While larger
studies are needed, these numbers suggest that apoptosis
is also at least partially cell autonomous in Rb-/- bipolar
cells. Finally, milder phenotypes may simply be more dif-
ficult to detect in animals with a low level of mosaic Rb
deletion. That is, detecting phenotypes associated with the
rapid apoptosis of certain cell types may be facilitated
when there is widespread deletion as in NesCre1 Rblox/lox
Table 2: Developmental phenotypes upon Rb deletion in the retina
Genotype Major Developmental Phenotypes References
Rb-/- chimera Apoptosis and ectopic mitosis at E16.5–E18.5 in inner layer
Loss of most Rb-/- cells from all retinal layers in adults
[63]
Rb-/-p107-/- chimera Apoptosis and retinal dysplasia at E17.5
Photoreceptor death by PND15
[65]
Rb-/-p130-/- chimera Inner layer proliferation at PND14 [71]
NesCre1; Rblox/lox Inner cell layer apoptosis and ectopic BrdU at E18.5
Photoreceptor degeneration in adult mosaic animals
[69]
NesCre1; Rblox/lox; p53-/- Inner cell cell layer apoptosis and ectopic BrdU at E18.5
Photoreceptor layer degeneration in adult mosaic animals
[69]
Chx10Cre; Rblox/lox Defective rod differentiation and rod cell death
Ectopic cells in outer plexiform layer
[73, 77, 78]
Chx10Cre; Rblox/lox; p107-/- Increased proliferation of cells expressing progenitor and amacrine markers at
PND30
[84]
αCre; Rblox/lox Increased apoptosis and proliferation in embryonic inner retina
Extension of normal proliferative period of retinal development
Ectopic proliferation of transition cells expressing markers of all 7 cell types
Death of most bipolar cells, ganglion cells and a subset of rods
Defective starburst amacrine cell differentiation
[67-69, 79]
αCre; Rblox/lox; p107-/- Increased apoptosis and proliferation over Rb mutants
Death of all peripheral cells except amacrine, horizontal and Müller cells
[67]
αCre; Rblox/lox; p130-/- Increased proliferation and apoptosis over Rb mutants
Severe degeneration from PND21 to PND31 
Hyperplasia at extreme periphery in all mice by PND31
[68]
αCre; Rblox/lox; E2f1-/- Rescue of inappropriate proliferation and apoptosis in bipolar, ganglion cells and rods Rescue 
of electroretinogram response
Defects in starburst amacrine cell differentiation remain
[79]
αCre; Rblox/lox; E2f2-/- Phenotype similar to Pax6 alphaCre Rblox/lox retinas [79]
αCre Rblox/lox; E2f3-/- (or E2f3a-/-) No rescue of cell death or ectopic cell division
Rescue of stabrurst amacrine cell differentiation
[79]Cell Division 2008, 3:9 http://www.celldiv.com/content/3/1/9
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retinas, or in the mid-far periphery of α-Cre Rblox/lox reti-
nas.
The phenotypes upon Rb loss are quite similar across stud-
ies of chimeras, α-Cre and NesCre1 mice, with milder phe-
notypes observed upon Chx10Cre-mediated  Rb
inactivation. Differences highlight the need to assess the
consequences of Rb deletion at different times across dif-
ferent cell types, and the need to better understand the
extent to which phenotypes are cell autonomous. Some of
these aims may be achieved by expressing Cre in a tempo-
rally and dosage controllable fashion using either viral
delivery or tamoxifen-inducible Cre-ER transgenics with
Cre-ER expression driven by cell-type specific promoters.
Effectors of Rb in the retina
The importance of specific E2f family members in mediat-
ing Rb dependent phenotypes is of great debate. Analyses
of E2f contribution to Rb-mutant developmental pheno-
types have been performed in the whole animal through
compound mutant studies, but the non-cell autonomous
consequences of placental dysfunction in Rb-/- embryos
complicate the interpretation of these results. Compound
mutant analysis specifically in the developing retina pro-
vides an excellent system to probe these interactions. The
importance of E2f1 in mediating the effects of Rb loss was
nicely shown by the Bremner group as compound muta-
tion of Rb and E2f1 rescued much of the proliferation and
apoptosis associated with Rb  deletion using the α-Cre
Rblox/lox system, and even restored response on the elec-
troretinogram, a measure of retinal electrical activity in
response to light [79]. Interestingly, these authors showed
that E2f1 loss did not rescue differentiation defects in Rb-
deficient starburst amacrine cells. In contrast, compound
mutation of Rb and E2F3a led to a rescue in starburst ama-
crine cell development suggesting that Rb/E2F3a interac-
tions promote the differentiation of these cells. While pro-
differentiation effects of pRB are often thought E2f-inde-
pendent, this is one example of pRB promoting the differ-
entiation of a cell type mediated through E2F.
It will be critical to dissect the pathway between Rb loss
and apoptosis in the developing retina. The above study
showed that apoptosis is E2f-dependent, but the E2f effec-
tors that contribute to apoptosis remain to be identified.
We were interested in whether p53 was downstream of Rb
inactivation in the retina [69]. Compound NesCre1 Rblox/
lox p53-/- double mutants did not exhibit rescue of apopto-
sis in the embryonic retinal ganglion cell layer. Also, the
loss of photoreceptors was not rescued in NesCre1 Rblox/lox
p53-/- animals exhibiting deletion of Rb in a mosaic pat-
tern. Rb loss has been linked to apoptosis as pRB is an
anti-apoptotic protein and many E2F  target genes are
apoptosis effectors [82]. Whether or not it is important to
suppress apoptosis for retinoblastoma development is a
point of contention, but in many human cancers, tumors
may not form unless an apoptotic pathway that is acti-
vated following Rb deletion is abrogated [83]. Elucidation
of the effectors of the p53-independent apoptosis down-
stream of Rb loss in the retina will be an important goal
for broadly understanding the events that synergize with
Rb loss to promote cancer.
Functional overlap among the pocket proteins
Data from chimeras and conditional mutants exhibiting
inactivation of Rb as well as p107 or p130 loss clearly illus-
trate tumor suppressive activity of p107 or p130 in the
context of Rb deficiency. It is not clear why retinoblastoma
manifests itself in mice only if p107 or p130 is inactivated
in addition to pRB. p107 expression is upregulated in
murine retinas lacking Rb  but not in human retina
explants with knockdown of RB expression, raising the
possibility that p107 upregulation prevents retinoblast-
oma in mice. [84]. However, increased expression of p107
in Rb-/- murine retinal cells has been reported only at
postnatal stages of retinal development, or in explant cul-
tures differentiated in vitro to recapitulate postnatal stages
of retinal development and not in embryonic Rb-/- retina
[69,84]. Importantly, an increase in proliferation occurs
in Rb-/- retinas at late time points in retinal development
[67-69]. As p107 is an E2f target gene typically expressed
in proliferating but not post-mitotic cells, the p107
increase has not been uncoupled from the cell cycle phe-
notypes associated with Rb loss at late stages in retinal
development. Other Rb targets, such as Cyclin E are found
strongly upregulated at both embryonic and postnatal
stages of retinal develoment in Rb-deficient retinas (D.M.
unpublished). It is also possible that functional overlap
among the pocket proteins without increased p107 or
p130 expression is critical for suppressing retinoblastoma
in mice. Indeed, p130 is a stronger suppressor of retino-
blastoma than p107 despite no alterations in p130 overall
levels upon Rb loss [68,69]. Factors that regulate pocket
protein activity may differ in their levels or activity in mice
compared to humans (either in the normal situation, or in
response to Rb loss) and many upstream regulators of
pocket proteins are known to be important for cell cycle
control in the retina. Cyclin D1-/- retinas are hypoplastic,
corresponding to altered pocket protein phosphorylation
[85]. High cyclin D1 levels likely promote normal progen-
itor cell expansion by keeping the pocket proteins inac-
tive. A decrease in the level of murine cyclin D1 occurs in
response to Rb family inactivation and this decrease may
contribute to retinoblastoma suppression in mice through
regulation of pocket protein activity [69]. Indeed, there is
a good correlation between the level of cyclin D1 and the
extent of p107 phosphorylation in retinas lacking Rb or
both Rb and p130 compared to controls. p27-/- retinas
exhibit an extension in the period of retinogenesis, impli-
cating  p27  in cell cycle exit in a subset of cells [86].Cell Division 2008, 3:9 http://www.celldiv.com/content/3/1/9
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p19(Ink4d) loss also extends the normal period of retinal
proliferation in the retina [87]. Whether upstream regula-
tors of p107 and p130 activity such as cyclin D1, p27 and
p19Ink4d can contribute to retinoblastoma in the context
of p107 or p130 being intact will be important to eluci-
date. It is likely that complex differences between mice
and humans in the levels and activity of multiple regula-
tors of the RB family contributes to the species difference
in retinoblastoma susceptibility. Thus, a broader under-
standing of the regulation of pRB, p107 and p130 in the
cell from which retinoblastoma is derived is needed.
Genetic interactions between Rb and p107 in the retina
Many of the developmental phenotypes associated with
retinal Rb loss are exacerbated upon additional mutation
of p107, revealing the functional overlap among these
family members [65,67,69]. Embryonic retinal prolifera-
tion and apoptosis are increased upon both Rb and p107
mutation. While rod and some cone photoreceptors sur-
vive when Rb is deleted in progenitor cells using the α-Cre
model, almost all are lost upon additional mutation of
p107 [67]. Nevertheless, many amacrine cells, horizontal
cells and Müller cells survived Rb and p107 deletion and a
subset of such animals developed retinoblastoma. Tumor
emergence from highly apoptotic retinas suggests that the
cell of origin of retinoblastoma in this model exhibits
intrinsic resistant to apoptosis. However, death resistance
is a relative term; despite the cell of origin surviving Rb/
p107 loss, emerging retinoblastomas can be highly apop-
totic [68] similar to human retinoblastomas. Secondary
alterations that confer evasion of apoptosis may indeed
contribute to the progression of retinoblastoma, but this
does not diminish the importance of the tumor cell of ori-
gin surviving when only three cell types survived in α-Cre
Rb/p107 DKOs [67]. Retinoblastomas from Rb/p107 chi-
meras or α-Cre Rblox/lox p107-/-  mice exhibited positive
immunostaining for multiple amacrine markers. Ama-
crine cells are a heterogeneous population with one esti-
mate of 29 subtypes [88]. Heterogeneity in the expression
of specific amacrine markers within a tumor and between
different tumors suggests that the tumors arise from a cell
capable of forming multiple amacrine subtypes. Also, hor-
izontal cells may also be present [89] and some cells
expressing glial cell markers [65,67,68] have been
observed in retinoblastomas lacking Rb  and  p107.
Together, these data raise the possibility that tumor cell of
origin is capable of generating multiple cell types.
Long latency of tumorigenesis and incomplete penetrance
suggests that Rb and p107 inactivation is not sufficient for
retinoblastoma. Thus, the Rb/p107 DKO models are ideal
for testing genes that potentially cooperate with loss of Rb
in retinoblastoma development, and to probe the nature
of the block(s) that must be overcome.
Genetic interactions between Rb and p130 in the retina
Interactions between Rb  and  p130  in the retina have
revealed roles for p130 in tumor suppression and retinal
development in α-Cre Rblox/lox  p130-/-,  NesCre1 Rblox/lox
p130-/- and in Rb-/-p130-/- chimeras [68,69,71]. In con-
trast to the embryonic disorganization in NesCre1 Rb/p107
DKO  retinas, histological defects were not found in
NesCre1 Rb/p130 DKO embryonic retinas [69]. In postna-
tal stages of retinal development, proliferation defects are
exacerbated by p12 in α-Cre Rb/p130DKOs, relative to α-
Cre Rblox/lox single mutants, revealing cooperation between
Rb and p130 in controlling cell cycle exit in late stages of
retinal development. By PND21, Rb-/- cells have all exited
the cell cycle, but cells in α-Cre Rblox/lox p130-/- retinas con-
tinue to inappropriately undergo S-phase entry and
exhibit the presence of cells with large aberrant nuclei
[68]. Proliferative phenotypes are coupled to high levels
of cell death, with severe degeneration in the α-Cre Rblox/
lox p130-/- retina. The extent to which this cell death is cell
autonomous has not yet been determined and it is possi-
ble that effects of Rb and p130 loss on certain cell types
may lead to the death of other cells through secondary
effects. Cell death is more pronounced in these animals
than α-Cre Rblox/lox p107-/- retinas, although some cells,
including horizontal cells, Müller cells and rare amacrine
cells survive at PND21. The survival and increase in hori-
zontal cells at this stage is a specific effect of Rb and p130
loss not observed upon Rb and p107 deletion.
Chimeric animals lacking Rb and p130, NesCre1 Rblox/lox
p130-/- and α-Cre Rblox/lox p130-/- mice all develop retino-
blastomas in which marker expression is heterogeneous
and includes the expression of amacrine markers
[68,69,71]. Regions of horizontal cell differentiation are
also found in α-Cre Rblox/lox p130-/- and NesCre1 Rblox/lox
p130-/-  retinoblastomas ([68] and D.M. unpublished).
Rb/p130 DKO retinoblastomas appear similar to Rb/p107
DKO  retinoblastomas upon histological examination,
and both resemble human retinoblastomas with neurob-
lastic differentiation (See Figure 1). Early lesions resem-
bling retinoblastoma, with Homer-Wright rosettes, were
observed by PND21 to PND31 in α-Cre Rblox/lox p130-/-
animals at the extreme periphery of the retina [68]. Our
observation of peripheral early lesions in α-Cre Rblox/lox
p107-/- animals points to a possible niche for the cell of
origin in both models. This may be similar to the localiza-
tion of tumors from PNMT-Tag animals [53,54] and there
also indications that early retinoblastomas in the LH-beta
T-Ag model preferentially locate to the retina preiphery
[90,91]. Notably, despite the death of most amacrine cells
away from early tumors at PND21, tumorigenesis is actu-
ally more prevalent in the α-Cre Rb/p130 DKO model than
the α-Cre Rb/p107 DKO model, suggesting that the tumors
may not derive from amacrine cells or that only a specific
subset of peripheral amacrine cells are sensitive to tumor-Cell Division 2008, 3:9 http://www.celldiv.com/content/3/1/9
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igenesis. [68]. Peripheral progenitor cells/stem cells,
Müller glia and horizontal cells are all alternative candi-
dates. Complete retinoblastoma penetrance is striking
given the high cell death and suggests that the cell of ori-
gin of Rb/p130 DKO tumors is less sensitive to apoptosis
than most cells in the retina.
Rb/p130 DKO retinoblastomas proceed to fill the vitreous,
and a subset invade the optic nerve and undergo tumor
extension into the brain, similar to advanced human
retinoblastoma. Tumors also metastasize to cervical
lymph nodes. The α-Cre Rb/p130 DKO model is a better
model for advanced retinoblastoma given the rapid tumor
kinetics. The importance of a mouse model of metastatic
retinoblastoma is evident from the poor prognosis of
humans with retinoblastoma metastasis [92,93]. In devel-
oped countries, retinoblastoma is well treated, with about
4% mortality, however, even with the best care, retino-
blastoma with CNS involvement exhibits extremely high
mortality [94]. The majority of children with retinoblast-
oma are born in less developed countries, where delayed
retinoblastoma diagnosis leads to extraocular disease; in
some parts of the world this results in mortality as high as
90% [94]. Better tumor-eradicating treatments are clearly
needed. The advanced tumor progression and the rapid,
consistent kinetics in the α-Cre Rblox/lox p130-/- animals
make this an excellent model for preclinical testing of
novel therapies for early and advanced retinoblastoma.
Effects of p107 vs. p130 loss in concert with Rb in the 
retina
The differences between Rb/p107 DKO and Rb/p130 DKO
models confirm that p107 and p130 have differing func-
tions. Distinct cell-type specific effects occur upon Rb and
p107 vs. Rb and p130 inactivation in the developing ret-
ina. Upon Rb and p130 loss, there is some increase in hor-
izontal cells even in the midst of high levels of retinal
degeneration [68]. This phenotype is not observed upon
Rb and p107 loss, implicating an important role for p130
in horizontal cell biology distinct from that of p107. There
is also evidence for an increased horizontal cell compo-
nent in Rb/p130 DKO compared to Rb/p107 DKO late
stage retinoblastomas [68]. The time to retinoblastoma
detection and tumor penetrance differs strongly, with
100% of Rb/p130 DKO animals developing bilateral retin-
oblastoma that emerge rapidly, while only a subset of Rb/
p107 DKO animals developing unilateral retinoblastoma
with long latency. The kinetics of tumorigenesis suggests
that there may be a difference in the number of secondary
alterations that arise. A critical question is whether the
tumors that eventually arise in Rb/p107 DKO animals
retain normal p130 function, or if there is selection to
evade a p130-induced differentiation block [67,69].
Despite differences in kinetics and cell type composition,
abundant data supports a model of a common cell of ori-
gin in Rb/p130 DKO vs. Rb/p107 DKO retinoblastomas.
First, there are similar histological characteristics includ-
ing the presence of Homer-Wright rosettes [68]. Rb/p107
DKO and Rb/p130 DKO retinoblastomas both exhibit var-
iable staining for different amacrine cell markers in chi-
meras,  NesCre1  and  Pax6 Cre mice and each of these
models exhibit the presence of some glial cells in the
tumor. In both Rb/p107 and Rb/p130 DKO models, we
have observed late proliferating cells at the extreme retina
periphery. Furthermore, the pattern of tumor dissemina-
tion is similar in very advanced tumors, with invasion of
the optic nerve and brain, and spread to cervical lymph
nodes (although such advanced tumors are rare in Rb/
p107 DKOs). Finally, secondary alteration analysis reveals
that tumors in both models undergo N-myc amplification,
suggestive of a common pathway to transformation [68].
"p107 single" mice
While Rb and p130 deletion leads to an increase in Calbi-
ndin-positive horizontal cells [68], the horizontal com-
partment is even further increased in another model in
which Chx10Cre drives Rblox/lox deletion in p130-/-, p107+/
Normal retina and retinoblastoma (A) Thin section of normal  murine retina with outer nuclear (ONL), inner nuclear layer  (INL) and ganglion cell layer (GCL) shown Figure 1
Normal retina and retinoblastoma (A) Thin section of 
normal murine retina with outer nuclear (ONL), inner 
nuclear layer (INL) and ganglion cell layer (GCL) shown. (B) 
Hematoxylin and Eosin (H+E) stain of human retinoblastoma 
with neuroblastic differentiation and Homer-Wright (HW) 
rosettes. (C) H+E staining of human retinoblastoma exhibit-
ing Flexner-Wintersteiner (FW) rosettes. Inset: M-opsin 
immunostaining showing evidence of cone differentiation. 
(D) H+E of primary murine retinoblastoma lacking Rb and 
p130 with Homer-Wright rosettes indicated.Cell Division 2008, 3:9 http://www.celldiv.com/content/3/1/9
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- animals, termed "p107 single" [95]. The authors pro-
posed that a differentiated horizontal cell is the retino-
blastoma cell-of-origin in this model. An important result
from the study is that differentiated horizontal cells with
their synaptic processes divide, which was convincingly
demonstrated. Interestingly, in PNMT-Tag  mice, func-
tional pRB family ablation in horizontal cells led to dis-
tinct effects depending on retinal topology [54]. PNMT-
Tag expression led to tumors in peripheral retina but not
in central retina, where horizontal cell death eventually
occurred; it will be important to carefully examine
whether peripheral vs. central horizontal cells also
respond differently in p107-single mice. While Dyer et al
(2007) conclude that the cell of origin is a horizontal cell,
the possibility of another cell type that generates the late-
stage tumors cannot be ruled out. The metastatic cells in
p107-single retinoblastomas did not resemble horizontal
cells either in ultrastructure or in cell marker expression,
suggesting that the retinoblastomas could derive from
cells that can produce both differentiated horizontal cells
and non-horizontal metastatic cells or that there may be a
mixed tumor phenotype with differing cells of origin. This
issue is also complicated by the labeling of amacrine cell
subsets by horizontal cell markers such as Calbindin and
Prox1 [96]. Overall, while the p107-single studies clearly
show that horizontal cells can divide and raise a very
interesting hypothesis regarding a possible cell of origin to
the tumors, deletion of these genes specifically in differen-
tiated horizontal cells will be necessary to prove this
hypothesis.
Tumor origins in human and murine retinoblastoma
Differentiated cells are not strong candidates for the cell of
origin of human retinoblastoma, given the evidence of
multipotent potential to human retinoblastoma cells
[32], although one cannot rule out the possibility of ded-
ifferentiation or transdifferentiation occurring. Retino-
blastoma occurs over a specific window in time following
eye development and is exceedingly rare in adults, sug-
gesting that critical mutational events occur during retinal
development. Also, mutation of RB is much more likely to
occur in a proliferating cell than a post-mitotic cell as
DNA replication and cell division can promote an initial
gene mutation or loss of heterozygosity. Despite differ-
ences in the cell type composition of murine vs. human
retinoblastomas, the cell of origin in human and mouse
retinoblastoma may both be a similar multipotent cell.
That is, the requirement to inactivate p107  or p130  in
addition to Rb in the mouse would be expected to mask
potential for the murine retinoblastoma cells to exhibit
photoreceptor character, as there is widespread death of
both rods and cones in the absence of Rb and p107 or Rb
and p130 when deleted in early progenitors using Pax6
alpha Cre [67,68]. Instead, in murine retinoblastoma we
observe the characteristics of the cells that best survive Rb
and p107 or Rb and p130 deletion, i.e. amacrine, Müller
and horizontal cells. The specific composition of tumor
cell types may be a result of the effects of p107 or p130 on
the survival, proliferation and differentiation of the retin-
oblastoma cell of origin and its daughters.
Spatial topology in human retinoblastoma
Observations of early lesions at the extreme retina periph-
ery in mouse retinoblastoma models raised the question
of whether spatial differences in the localization of
human retinoblastomas occur. Careful examination of
retinoblastoma topology has revealed that retinoblasto-
mas that arise in older children tend to occur at the
periphery of the retina, while those that occur in younger
children are typically central [97,98]. In humans, retinal
proliferation ceases in a region of central retina at 14
weeks of gestation and the non-proliferative region
expands to the extreme periphery by 30 weeks [26]; this
central to peripheral wave of cell cycle exit and differenti-
ation can explain some alterations in retinoblastoma
topology with age of detection. Other studies have
revealed that new retinoblastomas that arise in patients
following treatment for primary retinoblastoma occur
much more frequently at the retina periphery. For exam-
ple, in one study, 15 of 17 new retinoblastomas in bilat-
eral patients were found in the retina periphery [99] (also
see [100]. These findings are less easily explained under
the common view that retinogenesis ceases near the time
of birth. That is, in new retinoblastomas that arise follow-
ing treatment, the proliferative period of retinal develop-
ment would have long since ended before the
presumptive new tumor arose. Alternative possibilities
include the presence of an unappreciated population of
progenitors that reside in the retina periphery at a longer
time following birth than previously recognized, or a pop-
ulation of peripheral post-mitotic cells that may be capa-
ble of transformation. Indeed, there is recent evidence of
neuroprogenitors that reside at the periphery of the
mamalian retina. In a primate model of myopia, experi-
mental eyelid fusion led to the persistent proliferation of
neuroprogenitor cells at the retina periphery months after
birth [101]. Of note, control animals injected with BrdU
also exhibited proliferation at the retina periphery,
although at a much lower level than the stressed animals.
These studies revealed proliferation in the juvenile pri-
mate retina and modulation with a specific stress. In
patched heterozygous mice, persistent proliferation of cells
expressing the progenitor marker nestin was found at the
extreme retina periphery in adults, suggesting that the
hedgehog pathway may be important for the late prolifer-
ating cells [102]. Furthermore, cells with properties of
stem cells have been isolated from the pigmented epithe-
lial cells of the murine and human ciliary body [103-105].
The ciliary body is a peripheral eye structure adjacent to
neural retina, and close to the location where we firstCell Division 2008, 3:9 http://www.celldiv.com/content/3/1/9
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observe retinoblastomas in α-Cre Rblox/lox p130-/- or α-Cre
Rblox/lox  p107-/-  retinas [68]. Potential neuroprogenitor
cells in the mammalian retina may exhibit some similari-
ties to the cells of the ciliary marginal zone in fish and
amphibians. In these organisms, retinogenesis continues
into adulthood and stem cells clearly reside in the ciliary
marginal zone at the retina periphery (reviewed in [106]).
It will be critical to investigate the characteristics of the
peripheral late proliferating cells in murine retinoblast-
oma models as this will have important implications for
understanding the properties of a retinoblastoma cell of
origin.
A model for retinoblastoma development
An examination of the effects of Rb family loss in mouse
models suggests a model in which inactivation of RB
allows the proliferative period of retinal development to
be extended in the mutant cells. Upon mutation of both
Rb and p107 or Rb and p130, this phenotype is exacerbated
in mice. This model proposes that homozygous inactiva-
tion of RB  must occur during the normal proliferative
period of retinal development, and that this event
increases the chance of subsequent mutations by creating
a proliferative lesion balanced by cell cycle exit and differ-
entiation, or cell death. The loss of both copies of RB may
increase the rate of subsequent mutations, as was found in
embryonic stem (ES) cells, in which loss of Rb led to a dra-
matic increase in the rate of chromosomal alterations that
result in loss of a selectable marker [107]. Loss of Rb can
lead to chromosome segregation defects through misreg-
ulation of the expression of genes important for processes
such as centrosome duplication [108,109], mitotic check-
point control [110] or through impaired maintenance of
heterochromatin [111]. In humans, the time between the
end of retinal development and the appearance of retino-
blastoma may be the time period in which a smoldering
lesion caused by homozygous RB deletion during devel-
opment undergoes the secondary mutations needed for
tumor formation. In some cases, retinoblastoma may
form from a benign precursor lesion, retinoma that exhib-
its some features of senescence and has recently been
shown to exhibit less complex patterns of genetic altera-
tion than adjacent retinoblastoma [112,113]. Interest-
ingly, in retinomas, high levels of p130 were found, which
were not observed in adjacent retinoblastoma, suggesting
that evasion of p130 might be important for progression
of human retinoma to retinoblastoma [112]. One of the
essential current questions is the nature of the block to
proliferation/tumor expansion that must be overcome
even upon homozygous RB inactivation. Specifically, is
this a differentiation block, or must cell death or other
processes be overcome? Examination of the nature of sec-
ondary alterations will be needed to shed light on this
question.
Secondary genetic alterations in retinoblastoma
The two-hit hypothesis suggests that the first few years fol-
lowing birth reflects the time-interval for homozygous RB
mutation [1]. However, there is evidence that RB inactiva-
tion is not sufficient for retinoblastoma, as cytogenetic
studies have revealed consistent chromosomal abnormal-
ities in addition to RB deletion [114]. Early cytogenetic
studies have been extended by comparative genomic
hybridization (CGH) and array-CGH studies. Pooled data
across 6 studies reveal recurrent gain in 6p (54%), 1q
(53%), 2p (34%) and loss of 16q (32%), suggesting that
these regions may harbor oncogenes and tumor suppres-
sor genes, respectively [115-120], reviewed in [121]. The
vast majority of these data are from low-resolution stud-
ies; the advent of high-resolution oligonucleotide based
array-CGH promises to pinpoint minimal regions and
identify new, focal regions of change. In murine meta-
static retinoblastomas lacking Rb and p130, array CGH
revealed recurrent whole chromosomal gains at chromo-
some 1 (with synteny to the minimal region of gain in
human retinoblastoma at human 1q31-32) and 12 (with
synteny to the minimal region of gain at human 2p24)
[68]. Such findings of overlapping regions of frequent
chromosomal alterations in both murine and human
retinoblastoma are encouraging as they help to validate
the α-Cre Rb/p130 DKO mouse model. While alterations
in regions syntenic to human 6p and 16q were not
observed in α-Cre Rb/p130 DKO retinoblastomas, larger
studies are needed, and it is possible that loss of p130 in
the murine model may negate selection for 6p gain or 16q
loss. Indeed, RBL2 (p130) lies at 16q12 and is a good can-
didate tumor suppressor in this region in humans [121].
Genes in the minimal region of gain at human 6p22
include DEK as well as an interesting candidate, E2F3,
which conceivably could antagonize p130 upon overex-
pression. Use of mouse models will certainly help in
defining the critical genes in these regions, as mouse/
human comparisons have revealed highly concordant
genomic alterations in other tumor types and have
allowed for the identification and validation critical can-
cer-contributing genes [122,123]. As the topic of genomic
alterations in retinoblastoma has recently been compre-
hensively reviewed [121], here, I will briefly touch upon
on the human 1q31-32 and 2p candidate regions that
undergo gain or amplification in both murine and human
retinoblastomas.
Human 2p gain/N-MYC amplification
The most well characterized secondary alteration in
human retinoblastoma is gain or amplification of a region
of 2p that includes the N-MYC locus [118,124-126]. It is
not formally known that N-MYC is the gene in the ampli-
con selected for increased copy number, as other genes are
co-amplified, including the DEAD box gene DDX1. How-
ever, in α-Cre Rblox/lox p130-/- metastatic retinoblastomasCell Division 2008, 3:9 http://www.celldiv.com/content/3/1/9
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(3 of 16 metastases), amplicons containing N-myc were
also observed, ranging from 450 kb to 3.3 MB, and the
only known gene in the minimal region of amplification
was N-myc [68]. This result illustrates the power of high
density array-CGH analyses to resolve regions of altera-
tion to single genes and reveals the similarities between
human and mouse retinoblastomas. In both murine and
human retinoblastoma, low level gain of N-myc/N-MYC is
found more frequently that high level amplification. The
fact that N-Myc amplification is enriched in metastatic α-
Cre Rblox/lox p130-/- retinoblastoma suggests that this event
contributes to formation of more aggressive tumors but
how this is mediated is unknown. Genetic inactivation of
N-myc in the developing retina has revealed a critical role
for this gene in progenitor cell proliferation; this is in part
mediated by regulation of p27 levels [127]. Examination
of interactions between Rb and N-myc in the developing
retina and in retinoblastoma models should help us to
understand why these mutations synergize in tumorigen-
esis and to identify the critical N-myc target genes.
MDM4 and the p53 pathway in retinoblastoma
Many cytogenetic studies and CGH experiments have
demonstrated recurrent frequent gains in 1q [114,121].
While the regions of change typically include large regions
of 1q, smaller regions of gain in some tumors have been
used to define minimal common regions. Zielinski et al
(2005) noted a minimal region centered at 1q32.1-32.2,
that included the genes MDM4 and GAC1, and they also
identified a second common minimal region of gain at
1q22 [120]. MDM4 is related to MDM2 and both genes
cooperate to inhibit p53 function, with MDM4 an inhibi-
tor of p53 transcriptional activity [128]. Laurie et al [59]
showed by FISH that MDM4  undergoes copy number
increase and is overexpressed in retinoblastomas. They
report that 65% of human retinoblastomas had extra cop-
ies of MDM4 and 10% exhibited extra copies of MDM2.
Furthermore, transfection of MDM4 plasmid DNA into
newborn retinas in vivo led to more rapid tumorigenesis in
the α-Cre Rb/p107 DKO model. p53 is a good candidate
effector downstream of MDM4 as homozygous p53 loss
accelerated retinoblastoma development in vivo in Chx10-
Cre; Rblox/lox p53-/-; p107-/- animals compared to animals
with wild-type p53 [70,129]. In contrast to these findings,
in animals with inactivation of Rb on a p53-/- background,
(NesCre1 Rb lox/lox p53-/- mice) retinoblastomas did not
result [69], suggesting that p53 loss can impact upon retin-
oblastomas that have already been initiated, but that inac-
tivation of a second pocket protein in addition to Rb is
still critical. Based on experiments in culture using retinal
explants, the authors suggest that suppression of p53-
dependent apoptosis is crucial [59]. However, murine ret-
inal explants lacking Rb exhibit very low levels of apopto-
sis [73] compared to the high levels observed in Rb-/-
retinas in vivo (Table 2) and therefore may not be an ideal
correlate of Rb-dependent apoptosis in vivo. Indeed, Rb/
p53 compound mutation did not lead to suppression of
cell death associated with Rb  inactivation  in vivo [69].
Also, in chimeras with cells lacking Rb and p107, expres-
sion of a dominant negative p53 in Rb/p107 DKO pho-
toreceptors using an IRBP-p53DD transgene did not
rescue photoreceptor apoptosis in vivo [65]. It is also pos-
sible that p53  loss may contribute to retinoblastoma
through deregulation of p53 effectors that control the cell
cycle or maintain genomic stability. An absence of direct
p53  mutations in human retinoblastoma suggests that
other effectors downstream of MDM2/MDM4  may be
important. Candidates include the other p53 family mem-
bers p63 and p73, as well as targets such as Numb and p21
[130-132].
While  MDM4  is an excellent candidate retinoblastoma
oncogene gene on 1q, an important question is whether
there are other genes on chromosome 1q that drive selec-
tion for 1q gain. Findings of recurrent focal regions of
high-level gene amplification at 1q21 and 1q22
[118,133,120] and the identification of additional candi-
dates in the 1q32 minimal region of gain such as the
mitotic kinesin Kif14 [134,135] suggest that 1q harbors
multiple oncogenes. Unlike gliomas, which exhibit high-
level focal amplifications of MDM4 [136] examination of
a large panel of retinoblastomas with 1q gain revealed
low-level MDM4 gain in retinoblastoma [133]. Low-level
MDM4 gain, even of a single copy may allow a critical
threshold of MDM4 signaling to be reached and be phys-
iologically important for tumor development, but other
1q candidates should also be investigated. High-resolu-
tion array-CGH experiments using human retinoblastoma
samples will help to delineate the regions of focal high-
level gene amplifications on 1q most likely to harbor crit-
ical oncogenes.
The new data on possible p53 pathway involvement in
retinoblastoma provides interesting areas for future
research and the potential for novel, targeted therapy
(reviewed in [137]). Importantly, the addition of Nutlin,
an MDM4/MDM2 antagonist led to death of retinoblast-
oma cell lines and synergized with traditional chemother-
apy in an orthotopic retinoblastoma mouse model
[58,59]. It is clear that radiotherapy can synergize with
constitutional  RB  mutation in increasing secondary
tumors in patients [12]. The long term effects of systemic
chemotherapy on the incidence of secondary tumors in
germline RB mutant patients are not yet known, but it is
conceivable that chemotherapy could contribute to the
development of mutations that cooperate with RB muta-
tion at sites other than the eye. Also, systemic chemother-
apy can lead to debilitating side effects. Thus, localized
therapy based on the genetics of known frequent altera-
tions in retinoblastoma combined with localized chemo-Cell Division 2008, 3:9 http://www.celldiv.com/content/3/1/9
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therapy may provide a safer, effective treatment. It is
therefore essential that this pathway be better understood.
Summary
Research into retinoblastoma has revealed a great deal
about a malignant eye cancer, and has also led to many
general insights into the general mechanisms of tumor
suppression. Early genomic analyses of murine retino-
blastoma lacking Rb and p130 have revealed secondary
alterations similar to human retinoblastoma, suggesting
that the steps to tumorigenesis in the murine and human
retina are similar. Mouse models will be particularly pow-
erful for testing which candidate genes are important for
retinoblastoma progression. The novel models provide
valuable tools to help us understand the in vivo function
of pRB, to elucidate the properties of a cancer cell of origin
and to test preclinical therapies. We are now poised to
gain important insights into the steps between RB inacti-
vation in a developing retinal cell and the progression
towards retinoblastoma.
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